Trends of drug licensing in China: From bring-in to go-global

Trends of drug licensing in China: From bring-in to go-global

Blog Article

Global medicine R&D has shown a stabilized trend after fleeting prosperity lately.Despite of discouraging whole picture, the role of China in cross-border out-licensing activities of medical therapeutics keeps rising, which started since 2020 and further boosted in 2023.A jilungin dreaming tea holistic analysis of drug and technology licensing, involving Chinese enterprises from 2019 to 2023, revealed 807 license-in deals and 401 license-out deals.In-licensing showed a decreasing trend, while out-licensing was the opposite.

Increasing ingenuity of Chinese products has led to a shift from an import-oriented to an export-oriented situation, such as antibody-drug-conjugates, and cell/gene therapies.With supportive policies of old taylor whiskey 1933 price Chinese government, southeast Asia is becoming an important downstream market for out-licensed drugs.Biotech innovators are emerging as a dominant force with core innovation capacity.China is embracing international collaboration by showing favorable markets and high-level innovative products.